Use of EGFR biomarkers for the treatment of gastric cancer with anti-EGFR agents
US10442862B2 · kind B2 · utility
2Cited by
0References
8Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 14, 2014 |
| Grant date | Oct 15, 2019 |
| Priority date | — |
| Expiry date | Oct 9, 2034 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2333/71
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to methods for treating gastric neoplasias, in particular treating patients who have been previously determined to have an EGFR biomarker. Gastric carcinoma (GC) is one of the most common and deadest cancers with −1 million diagnoses and −0.7 million deaths each year worldwide, with high incidence in Eastern Asia.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.